Levosimendan Altan

Levosimendan, the active ingredient in Levosimendan Altan, is a calcium sensitizer and K‑ATP channel opener presented as an intravenous solution for intravenous use. It treats acute decompensated heart failure and low‑output heart failure in adult patients.

GNH USA supplies Levosimendan Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of heart‑failure conditions where enhanced cardiac contractility is required.

Acute decompensated heart failure: improves hemodynamics and reduces symptoms of congestion. Low‑output heart failure: increases cardiac output and tissue perfusion. Cardiogenic shock (off‑label): may provide hemodynamic support when conventional therapy is insufficient.

Levosimendan may cause a range of adverse reactions, from mild to severe. Monitoring and prompt management are essential.

Common Side Effects: - Hypotension: drop in blood pressure, especially after loading dose. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of skin. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan requires careful patient assessment and monitoring before and during infusion. - Blood pressure monitoring: check for hypotension before initiation and regularly during infusion. - Cardiac rhythm assessment: observe for arrhythmias, especially in patients with pre‑existing conduction disorders. - Dose adjustment: consider reduced dosing in severe renal or hepatic impairment. - Concomitant vasodilators: avoid or use with caution when combined with other potent vasodilators. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, influencing cardiovascular stability.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase levosimendan exposure. - Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic effect. - Diuretics: monitor electrolyte balance and volume status. - ACE inhibitors/ARBs: watch for additive blood‑pressure lowering. - Calcium channel blockers: potential additive vasodilation. - Antiarrhythmic agents: observe for rhythm changes.